Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab

@inproceedings{Xing2016GeneTF,
  title={Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab},
  author={Man Rong Xing and Xiang Wang and Yudan Chi and Dongming Zhou},
  booktitle={Oncotarget},
  year={2016}
}
Cetuximab is a chimeric monoclonal antibody, approved to treat patients with metastatic colorectal cancer (mCRC), head and neck squamous cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC) for years. It functions by blocking the epidermal growth factor receptor (EGFR) from receiving signals or interacting with other proteins. Although the demand for cetuximab for the treatment of cancer patients in clinics is increasing, the complicated techniques involved and its high cost limit its… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Stable antibody expression at therapeutic levels using the 2A peptide

  • Nature Biotechnology
  • 2005
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 2 EXCERPTS

EGFR Signaling in Colorectal Carcinoma

  • Pathology research international
  • 2011
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…